PTC Therapeutics (NASDAQ:PTCT) Releases Quarterly Earnings Results, Misses Expectations By $0.76 EPS

Key Points

• PTC Therapeutics missed earnings expectations: The company reported a quarterly loss of $0.62 per share versus the $0.14 consensus estimate, although revenue rose 69.6% year over year to $357.81 million, exceeding forecasts.
• Management raised its outlook after a record quarter: 2026 product-revenue guidance increased to $960 million–$990 million, with cash-flow breakeven still expected this year. SEPHIENCE revenue reached $182 million, supported by more than 2,000 active patients worldwide.
• The pipeline offers growth potential but faces execution risks: PTC expects to complete its ST-920 gene-therapy filing in the fourth quarter, while mature DMD products face generic and one-time-order pressure; the Votoplam FDA meeting was also delayed to early 2027.

PTC Therapeutics (NASDAQ:PTCT - Get Free Report) announced its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.14 by ($0.76), FiscalAI reports. The firm had revenue of $357.81 million for the quarter, compared to analyst estimates of $306.43 million. The company's revenue was up 69.6% compared to the same quarter last year. During the same quarter last year, the firm posted $0.20 EPS.

Here are the key takeaways from PTC Therapeutics' conference call:

• Guidance was raised after a record quarter: Third-quarter total revenue reached $358 million, including $276 million in product revenue, and 2026 product revenue guidance increased to $960 million–$990 million. Management also reiterated its expectation to reach cash-flow breakeven this year.
• SEPHIENCE launch momentum remains strong: Global SEPHIENCE revenue was $182 million, up more than 20% sequentially, with over 2,000 active patients worldwide and strong adherence. PTC said the U.S. launch is entering a durable growth phase and maintained its confidence in a $2 billion-plus peak-sales opportunity.
• ST-920 adds a potentially near-term growth driver: PTC expects to complete its rolling BLA submission for the Fabry gene therapy in the fourth quarter, with potential approval and launch in 2027. The company said the $111 million acquisition could be accretive in 2027 and noted ST-920’s RMAT designation may support priority review.
• Mature DMD products face increasing pressure: A new Emflaza generic entrant has significantly reduced pricing, while Translarna’s third-quarter revenue benefited from an unexpected Russian government order that PTC does not expect to repeat in the fourth quarter.
• Votoplam’s regulatory discussion was delayed: The FDA Type C meeting on the Huntington’s disease program is now expected in the first quarter of 2027 rather than late 2026, although global enrollment in the 770-patient INVEST-HD Phase III study continues.

PTC Therapeutics Trading Up 2.3%

PTCT stock traded up $1.44 during midday trading on Thursday, hitting $64.46. The stock had a trading volume of 1,524,172 shares, compared to its average volume of 996,871. The firm has a market capitalization of $5.38 billion, a price-to-earnings ratio of -111.14, a P/E/G ratio of 1.90 and a beta of 0.49. PTC Therapeutics has a 52 week low of $58.80 and a 52 week high of $90.87. The stock has a 50-day simple moving average of $65.57 and a 200 day simple moving average of $70.87.

Insiders Place Their Bets

In other news, VP Mark Boulding sold 435 shares of the firm's stock in a transaction dated Tuesday, October 6th. The shares were sold at an average price of $64.16, for a total transaction of $27,909.60. Following the completion of the transaction, the vice president directly owned 105,272 shares of the company's stock, valued at approximately $6,754,251.52. This trade represents a 0.41% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Michael Schmertzler sold 2,500 shares of the company's stock in a transaction dated Wednesday, October 14th. The shares were sold at an average price of $59.61, for a total transaction of $149,025.00. Following the completion of the sale, the director directly owned 1,291,594 shares in the company, valued at approximately $76,991,918.34. The trade was a 0.19% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 77,370 shares of company stock worth $5,322,261 over the last 90 days. Corporate insiders own 5.30% of the company's stock.

Analysts Set New Price Targets

PTCT has been the subject of a number of research reports. Morgan Stanley increased their price target on shares of PTC Therapeutics from $93.00 to $104.00 and gave the company an "overweight" rating in a report on Friday, July 31st. Zacks Research downgraded shares of PTC Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Thursday, August 6th. Barclays upped their price objective on shares of PTC Therapeutics from $120.00 to $122.00 and gave the company an "overweight" rating in a research report on Friday, August 14th. UBS Group assumed coverage on shares of PTC Therapeutics in a research note on Thursday, October 15th. They issued a "buy" rating and a $90.00 target price for the company. Finally, Raymond James Financial set a $106.00 target price on PTC Therapeutics in a research report on Tuesday, October 20th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, three have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $94.93.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines for rare diseases. Its research programs include small-molecule treatments, gene therapies and other approaches designed to address conditions with limited or no available treatment options.

The company's commercial portfolio has included Emflaza (deflazacort), a corticosteroid approved in the United States to treat Duchenne muscular dystrophy, and Upstaza (eladocagene exuparvovec), a gene therapy authorized in the European Union for aromatic L-amino acid decarboxylase deficiency.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.